Current Medical Research and Opinion

Journal Information
ISSN / EISSN : 03007995 / 14734877
Current Publisher: Informa UK Limited (10.1080)
Former Publisher: Informa Healthcare (10.3111) , Informa Healthcare (10.1185)
Total articles ≅ 6,760
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
LOCKSS
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Qian Cai, John J. Sheehan, Bingcao Wu, Larry Alphs, Nancy Connolly, Carmela Benson
Current Medical Research and Opinion pp 1-1; doi:10.1080/03007995.2019.1671087

Abstract:Objectives: To assess characteristics and healthcare costs associated with pharmacologically-treated episodes of treatment-resistant depression (TRD) in patients with major depressive disorder (MDD). Methods: Patients aged ≥18 years with continuous health plan enrollment for ≥12 months before and after a newly observed MDD diagnosis (observed between 1/1/2010 and 12/31/2015) were included in this retrospective claims-based analysis. A pharmacologically-treated episode was defined as beginning at the date of the first MDD diagnosis and ending when a gap of 180 days occurred between MDD diagnoses, or when a gap of 180 days occurred following the end of the antidepressant (AD)/antipsychotic (AP) drug supply. When such a gap occurred, the episode end date was determined to be either the date of the last MDD diagnosis or date of the end of AD/AP drug supply, whichever was later. An episode was considered TRD if ≥3 AD regimens occurred. Episode duration, medication regimens used, and relapse hospitalization were reported for TRD and non-TRD MDD episodes. Total all-cause and per-patient-per-month (PPPM) healthcare costs (in 2016 $) were estimated. Results: Of 48,440 patients identified with ≥1 AD-treated MDD episode, the mean (SD) age was 39 (15) years, and 62% were female. Of all episodes, 7% were TRD, with a mean duration of 571 (285) days vs. 200 (198) days for non-TRD MDD episodes. Mean total all-cause costs were $19,626 ($44,160) for TRD and $7,440 ($25,150) for non-TRD MDD episodes. Conclusions: Results show TRD episodes are longer and costlier than non-TRD MDD episodes, and that higher costs are driven by episode duration. Longer episodes imply protracted suffering for patients with TRD and increased burden on caregivers. Effective intervention to shorten TRD episodes may lessen disease burden and reduce costs.
Rosalba Rosato, Daniela Di Cuonzo, Giuliana Ritorto, Laura Fanchini, Sara Bustreo, Patrizia Racca, Eva Pagano
Current Medical Research and Opinion pp 1-1; doi:10.1080/03007995.2019.1670475

The publisher has not yet granted permission to display this abstract.
Dirk Deleu, Beatriz Canibaño, Boulenouar Mesraoua, Gholamreza Adeli, Mohamed S Abdelmoneim, Yasir Ali, Osama Elalamy, Gayane Melikyan, Amir Boshra
Current Medical Research and Opinion pp 1-1; doi:10.1080/03007995.2019.1669378

The publisher has not yet granted permission to display this abstract.
Jacquelyn G. Wilson, Almasa Bass, Glenn C. Pixton, Gernot Wolfram, Richard L. Rauck
Current Medical Research and Opinion pp 1-9; doi:10.1080/03007995.2019.1661679

Abstract:Objective: To assess the impact of age on the safety and tolerability of ALO-02, an abuse-deterrent opioid formulation consisting of oxycodone hydrochloride and sequestered naltrexone hydrochloride, in patients with chronic pain. Methods: Data from two clinical studies in patients with chronic low back pain or chronic non-cancer pain were analyzed. Patients aged ≥18 years who required continuous around-the-clock opioid analgesia for an extended period were grouped into ≥65 years and <65 years age groups. Treatment-emergent adverse events (TEAEs), use of concomitant medications, clinical laboratory measurements, and occurrences of opioid withdrawal using reported AEs and Clinical Opiate Withdrawal Scale (COWS) scores assessed safety. Data pooling was employed for the titration and maintenance phases of both studies. Results: 805 and 436 patients received ≥1 dose of ALO-02 in the titration and maintenance phases, respectively; 121 (15.0%) and 83 (14.6%) patients were aged ≥65 years in the titration and maintenance phase, respectively. Average doses of ALO-02 were lower in the older patients in both phases. Incidences of TEAEs were comparable between age groups in both phases and generally lower in the maintenance phase. Concomitant medications were taken more often by patients aged ≥65 years. Incidences of potentially clinically significant laboratory results were low in both phases with no clinically important differences between age groups. There were few reports of opioid withdrawal events as assessed by reported AEs and COWS scores. One patient aged ≥65 years experienced an AE of opioid withdrawal. Conclusions: The safety and tolerability of ALO-02 is similar in those aged ≥65 years and those aged <65 years with chronic pain. ClinicalTrials.gov identifiers: NCT01571362, NCT01428583.
Che-Hung Pao, Yu Ko
Current Medical Research and Opinion pp 1-5; doi:10.1080/03007995.2019.1662990

The publisher has not yet granted permission to display this abstract.
Jörg Michel, Michael Hofbeck, Ann-Kathrin Peper, Matthias Kumpf, Felix Neunhoeffer
Current Medical Research and Opinion pp 1-6; doi:10.1080/03007995.2019.1663689

The publisher has not yet granted permission to display this abstract.
Shweta Shah, Leon Raskin, David Cohan, Morganna Freeman, Omid Hamid
Current Medical Research and Opinion pp 1-10; doi:10.1080/03007995.2019.1662688

The publisher has not yet granted permission to display this abstract.
Roger S. McIntyre, Rita Prieto, Patricia Schepman, Yu-Chen Yeh, Matthieu Boucher, Ahmed Shelbaya, Richard Chambers, Xin Gao, Elizabeth Pappadopulos
Current Medical Research and Opinion pp 1-9; doi:10.1080/03007995.2019.1652053